{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:14:16Z","timestamp":1792192456706,"version":"4.4.0"},"reference-count":311,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.clinbiochem.2013.06.012","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T16:04:15Z","timestamp":1371744255000},"page":"1323-1338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":293,"title":["Adverse drug reactions induced by valproic acid"],"prefix":"10.1016","volume":"46","author":[{"given":"Radu M.","family":"Nanau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela G.","family":"Neuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0005","author":"National Institutes of Health"},{"issue":"Suppl. 7","key":"10.1016\/j.clinbiochem.2013.06.012_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1528-1167.2012.03712.x","article-title":"Why are antiepileptic drugs used for nonepileptic conditions?","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eplepsyres.2008.11.018","article-title":"Antiepileptic drug utilization in Taiwan: analysis of prescription using National Health Insurance database","volume":"84","author":"Hsieh","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.1736","article-title":"Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis","volume":"18","author":"Tsiropoulos","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0025","doi-asserted-by":"crossref","first-page":"iii-206","DOI":"10.3310\/hta11390","article-title":"A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder","volume":"11","author":"Soares-Weiser","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1517\/17425250902911455","article-title":"A review of valproate in psychiatric practice","volume":"5","author":"Haddad","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0035","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1042\/BST0371126","article-title":"Structure\u2013function studies for the panacea, valproic acid","volume":"37","author":"Terbach","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1108\/09526861211192395","article-title":"Valproate in acute mania: is our practice evidence based?","volume":"25","author":"Vasudev","year":"2012","journal-title":"Int J Health Care Qual Assur"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0045","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1526-4610.2011.02058.x","article-title":"Pharmacological synergy: the next frontier on therapeutic advancement for migraine","volume":"52","author":"Blumenfeld","year":"2012","journal-title":"Headache"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0050","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.neurol.2009.01.050","article-title":"Antiepileptic drugs for the prevention of pediatric migraine","volume":"165","author":"Cuvellier","year":"2009","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-3-5","article-title":"Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents","volume":"3","author":"Tan","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.brainresbull.2009.09.003","article-title":"Valproic acid as a promising agent to combat Alzheimer's disease","volume":"81","author":"Zhang","year":"2010","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0065","first-page":"CD004028","article-title":"Valproate for schizophrenia","volume":"3","author":"Schwarz","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0070","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hup.1236","article-title":"Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia","volume":"26","author":"Larrison","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0075","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.yebeh.2012.08.029","article-title":"Health plan paid cost of epilepsy in 2009 in the U.S.","volume":"25","author":"Wilner","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/17425255.2012.645535","article-title":"Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects","volume":"8","author":"Jankovic","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0085","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1345\/aph.1Q349","article-title":"Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies","volume":"45","author":"Yamada","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"Suppl. 5","key":"10.1016\/j.clinbiochem.2013.06.012_bb0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1528-1167.2006.00871.x","article-title":"Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs","volume":"47","author":"Perucca","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0095","series-title":"Drug-induced hepatotoxicity","first-page":"637","article-title":"Antiepileptic drugs","author":"Zimmerman","year":"1996"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0009-9120(01)00217-X","article-title":"CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity","volume":"34","author":"Neuman","year":"2001","journal-title":"Clin Biochem"},{"issue":"Suppl. 2","key":"10.1016\/j.clinbiochem.2013.06.012_bb0105","first-page":"S23","article-title":"Hepatic considerations in the use of antiepileptic drugs","volume":"28","author":"Dreifuss","year":"1987","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0110","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0887-8994(96)00318-9","article-title":"Medium chain acyl-CoA dehydrogenase deficiency and fatal valproatetoxicity","volume":"16","author":"Nj\u00f8lstad","year":"1997","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1203\/00006450-197503000-00005","article-title":"Production of the features of Reye's syndrome in rats with 4-pentenoic acid","volume":"9","author":"Glasgow","year":"1975","journal-title":"Pediatr Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(84)92139-1","article-title":"Heterozygous antitrypsin deficiency and valproate hepatotoxicity","volume":"1","author":"Moore","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0125","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.1840040609","article-title":"The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies","volume":"4","author":"Kesterson","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0130","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1528-1157.1987.tb03640.x","article-title":"Hepatotoxicity in rat following administration of valproic acid","volume":"28","author":"Sugimoto","year":"1987","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/toxsci\/kfq294","article-title":"Role of oxidative metabolism in the effect of valproic acid on markers of cell viability, necrosis, and oxidative stress in sandwich-cultured rat hepatocytes","volume":"118","author":"Kiang","year":"2010","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.taap.2011.03.004","article-title":"Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: role of biotransformation and temporal relationship with onset of toxicity","volume":"252","author":"Kiang","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0145","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bcp.2011.07.103","article-title":"Valproic acid utilizes the isoleucine breakdown pathway for its complete \u03b2-oxidation","volume":"82","author":"Lu\u00eds","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0150","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","article-title":"New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA","volume":"55","author":"Aires","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.taap.2012.08.018","article-title":"Assessment of the role of in situ generated (E)-2,4-diene-valproic acid in the toxicity of valproic acid and (E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes","volume":"264","author":"Surendradoss","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0160","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2125.2010.03754.x","article-title":"Drug-induced hepatic injury in children: a case\/non-case study of suspected adverse drug reactions in VigiBase","volume":"70","author":"Ferrajolo","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clineuro.2009.12.014","article-title":"Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients","volume":"112","author":"Zeng","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0170","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.neurol.2011.02.035","article-title":"Relationship between plasma concentrations of valproic acid and hepatotoxicity in patients receiving high doses","volume":"167","author":"Ghozzi","year":"2011","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0175","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/YIC.0b013e328333ac1b","article-title":"Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial","volume":"25","author":"Bowden","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/qjmed\/hch007","article-title":"Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study","volume":"97","author":"Kochar","year":"2004","journal-title":"QJM"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0185","first-page":"131","article-title":"Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide","volume":"108","author":"Neyns","year":"2008","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0190","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1157\/13128011","article-title":"Valproic acid induced-idiosyncratic hepatotoxicity","volume":"69","author":"Mata Zubillaga","year":"2008","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0195","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/hep.1840020520","article-title":"Sodium valproate in the induction of unusual hepatotoxicity","volume":"2","author":"Zafrani","year":"1982","journal-title":"Hepatology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0200","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.1840020513","article-title":"Valproate-induced hepatic injury: analyses of 23 fatal cases","volume":"2","author":"Zimmerman","year":"1982","journal-title":"Hepatology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0205","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1528-1157.1988.tb03757.x","article-title":"Fatal liver failure in 16 children with valproate therapy","volume":"29","author":"Scheffner","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0210","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/WNL.39.2.201","article-title":"Valproic acid hepatic fatalities. II. US experience since 1984","volume":"39","author":"Dreifuss","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0215","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eplepsyres.2009.04.004","article-title":"Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment","volume":"86","author":"Luef","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0220","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00431-009-0927-y","article-title":"Nonalcoholic fatty liver disease during valproate therapy","volume":"168","author":"Verrotti","year":"2009","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0225","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.yebeh.2010.12.012","article-title":"Nonalcoholic fatty liver disease in adolescents receiving valproic acid","volume":"20","author":"Verrotti","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0230","first-page":"990","article-title":"Reversible valproate fulminant hepatic failure","volume":"5","author":"Colletti","year":"1986","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0235","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.1840020622","article-title":"Valproate-induced hepatic steatogenesis in rats","volume":"2","author":"Lewis","year":"1982","journal-title":"Hepatology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0240","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/01480540903207076","article-title":"Drugs interfering with mitochondrial disorders","volume":"33","author":"Finsterer","year":"2010","journal-title":"Drug Chem Toxicol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0245","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.seizure.2012.03.003","article-title":"Epilepsy in mitochondrial disorders","volume":"21","author":"Finsterer","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0250","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/17425255.2012.644535","article-title":"Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders","volume":"8","author":"Finsterer","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0255","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s004310050663","article-title":"Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy","volume":"156","author":"Lam","year":"1997","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0260","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1034\/j.1600-0676.2000.020004346.x","article-title":"Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure","volume":"20","author":"Kr\u00e4henb\u00fchl","year":"2000","journal-title":"Liver"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0265","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/088307380001500709","article-title":"Evidence that Alpers-Huttenlocher syndrome could be a mitochondrial disease","volume":"15","author":"Rasmussen","year":"2000","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0270","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.20079","article-title":"POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion","volume":"55","author":"Naviaux","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0275","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.seizure.2010.01.002","article-title":"POLG DNA testing as an emerging standard of care before institutingvalproic acid therapy for pediatric seizure disorders","volume":"19","author":"Saneto","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0280","doi-asserted-by":"crossref","first-page":"CR203","DOI":"10.12659\/MSM.881716","article-title":"Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed post mortem by identification of p.W748S mutation in POLG gene","volume":"17","author":"Pronicka","year":"2011","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0285","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bbadis.2010.02.003","article-title":"Functional analysis of H. sapiens DNA polymerase gamma spacer mutation W748S with and without common variant E1143G","volume":"1802","author":"Palin","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0290","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B","article-title":"Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers' syndrome","volume":"45","author":"Naviaux","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0295","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/hep.23891","article-title":"Polymerase \u03b3 gene POLG determines the risk of sodium valproate-induced liver toxicity","volume":"52","author":"Stewart","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0300","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1034\/j.1399-3046.2000.00115.x","article-title":"Fatal deterioration of neurological disease after orthotopic liver transplantation forvalproic acid-induced liver damage","volume":"4","author":"Kayihan","year":"2000","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0305","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/adc.2007.122911","article-title":"Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1)","volume":"93","author":"McFarland","year":"2008","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0310","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00401-003-0698-x","article-title":"Features of cell death in brain and liver, the target tissues of progressive neuronal degeneration of childhood with liver disease (Alpers-Huttenlocher disease)","volume":"106","author":"Simonati","year":"2003","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0315","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.braindev.2007.08.009","article-title":"Alpers syndrome with prominent white matter changes","volume":"30","author":"Bao","year":"2008","journal-title":"Brain Dev"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0320","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1528-1167.2008.01544.x","article-title":"Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onsetAlpers syndrome and status epilepticus","volume":"49","author":"Uusimaa","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0325","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/NEN.0b013e3181839b2d","article-title":"Clonally expanded mitochondrial DNA mutations in epileptic individuals with mutated DNA polymerase gamma","volume":"67","author":"Zsurka","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0330","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1528-1167.2008.01877.x","article-title":"Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features","volume":"50","author":"Wolf","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0335","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2377-11-4","article-title":"Molecular and biochemical characterisation of a novel mutation in POLG associated with Alpers syndrome","volume":"11","author":"Schaller","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0340","doi-asserted-by":"crossref","first-page":"19501","DOI":"10.1074\/jbc.M109.011940","article-title":"Disease mutations in the human mitochondrial DNA polymerase thumb subdomain impart severe defects in mitochondrial DNA replication","volume":"284","author":"Kasiviswanathan","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0345","doi-asserted-by":"crossref","first-page":"31341","DOI":"10.1074\/jbc.M506762200","article-title":"The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit","volume":"280","author":"Chan","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0350","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1093\/hmg\/ddl424","article-title":"Modulation of the W748S mutation in DNA polymerase gamma by the E1143Gpolymorphismin mitochondrial disorders","volume":"15","author":"Chan","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0355","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/brain\/awl097","article-title":"The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases","volume":"129","author":"Tzoulis","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0360","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ana.20498","article-title":"POLG mutations and Alpers syndrome","volume":"57","author":"Davidzon","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0365","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/brain\/awn007","article-title":"POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection","volume":"131","author":"Engelsen","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0370","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2005.12.026","article-title":"Molecular diagnosis of Alpers syndrome","volume":"45","author":"Nguyen","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0375","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/archneurol.2011.124","article-title":"Novel POLG splice site mutation and optic atrophy","volume":"68","author":"Milone","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0380","doi-asserted-by":"crossref","first-page":"9072","DOI":"10.1093\/nar\/gkr618","article-title":"Clustering of Alpers disease mutations and catalytic defects in biochemical variants reveal new features of molecular mechanism of the human mitochondrial replicase, Pol \u03b3","volume":"39","author":"Euro","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0385","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.1002\/humu.20824","article-title":"Molecular and clinical genetics of mitochondrial diseases due to POLG mutations","volume":"29","author":"Wong","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0390","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/jmg.2008.058180","article-title":"Novel POLG1 mutations associated with neuromuscular and liver phenotypes in adults and children","volume":"46","author":"Stewart","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0395","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-0404.2009.01212.x","article-title":"Mitochondrial DNA depletion in progressive external ophthalmoplegia caused by POLG1 mutations","volume":"120","author":"Tzoulis","year":"2009","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0400","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.ejhg.5201002","article-title":"Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy","volume":"11","author":"van Goethem","year":"2003","journal-title":"Eur J Hum Genet"},{"issue":"Suppl. 8","key":"10.1016\/j.clinbiochem.2013.06.012_bb0405","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1528-1167.2011.03223.x","article-title":"Mitochondrial function and pathology in status epilepticus","volume":"52","author":"Bindoff","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0410","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11011-006-9039-9","article-title":"Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA","volume":"22","author":"Lin","year":"2007","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0415","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jns.2010.06.029","article-title":"MELAS syndrome associated with both A3243G-tRNALeu mutation and multiple mitochondrial DNA deletions","volume":"296","author":"Aharoni","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0420","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.jemermed.2009.10.021","article-title":"Adult-onset of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome presenting as acute meningoencephalitis: a case report","volume":"43","author":"Hsu","year":"2012","journal-title":"J Emerg Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0425","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1093\/hmg\/ddn265","article-title":"The A3243G tRNALeu(UUR) MELAS mutation causes amino acid misincorporation and a combined respiratory chain assembly defect partially suppressed by overexpression of EFTu and EFG2","volume":"17","author":"Sasarman","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0430","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bbrc.2011.03.094","article-title":"A whole mitochondrial genome screening in a MELAS patient: a novel mitochondrial tRNA(Val) mutation","volume":"407","author":"Mezghani","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0435","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/01.wnl.0000307661.98694.c3","article-title":"Melas associated with mutations in the polg1 gene","volume":"70","author":"Tzoulis","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0440","first-page":"1053","article-title":"Melas associated with mutations in the polg1 gene","volume":"70","author":"Deschauer","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0445","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1177\/0883073811402204","article-title":"Valproate-induced worsening of seizures: clue to underlying diagnosis","volume":"26","author":"Dhamija","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0450","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.genhosppsych.2011.12.009","article-title":"Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management","volume":"34","author":"Chopra","year":"2012","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0455","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/JCP.0b013e31817275b6","article-title":"A case of hyperammonemic encephalopathy after 11years of valproate therapy","volume":"28","author":"Stewart","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0460","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.annfar.2011.05.019","article-title":"Acute valproic acid intoxication: interest of a treatment by extracoporeal elimination combined with l-carnitine","volume":"30","author":"Alluin","year":"2011","journal-title":"Ann Fr Anesth Reanim"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0465","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jocn.2010.08.022","article-title":"Progressive encephalopathy with cerebral oedema and infarctions associated with valproate and diazepam overdose","volume":"18","author":"Rupasinghe","year":"2011","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0470","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/cap.2010.2052","article-title":"Bipolar disorder and valproate-induced hyperammonemic encephalopathy in an adolescent with diabetes","volume":"20","author":"Young","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0475","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/0269881109102635","article-title":"Clinical alertness to valproic acid-induced hyperammonemia\u2014two case reports","volume":"24","author":"Shan","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0480","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.amjmed.2010.02.029","article-title":"Adult nonhepatic hyperammonemia: a case report and differential diagnosis","volume":"123","author":"LaBuzetta","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0485","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/j.revmed.2010.06.010","article-title":"Valproate-induced hyperammonemic encephalopathy","volume":"32","author":"Granel","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0490","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/00952991003674804","article-title":"Hyperammoneic encephalopathy, valproic acid, and benzodiazepine withdrawal: a case series","volume":"36","author":"Starer","year":"2010","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0495","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/WNF.0b013e3181ac3615","article-title":"Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate","volume":"32","author":"Deutsch","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0500","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1875-9572(09)60010-3","article-title":"Valproate-induced hyperammonemic encephalopathy","volume":"49","author":"Chou","year":"2008","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0505","first-page":"484","article-title":"Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient","volume":"43","author":"Abreu","year":"2009","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0510","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1213\/ANE.0b013e318228a001","article-title":"Perioperative exacerbation of valproic acid-associated hyperammonemia: a clinical and genetic analysis","volume":"113","author":"Bezinover","year":"2011","journal-title":"Anesth Analg"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0515","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1460-9592.2011.03633.x","article-title":"Valproate-induced hyperammonemia and seizures: perioperative concerns","volume":"21","author":"Garg","year":"2011","journal-title":"Paediatr Anaesth"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0520","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.yebeh.2011.05.006","article-title":"Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism","volume":"21","author":"Gomez-Iba\u00f1ez","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0525","first-page":"389","article-title":"A case of hyperammonaemic encephalopathy due to valproic acid","volume":"69","author":"Prins","year":"2011","journal-title":"Neth J Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0530","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3109\/00365521003624169","article-title":"Valproate-induced hyperammonemic encephalopathy, rapidly improved by i.v. carnitine and glucose\/thiamine","volume":"45","author":"B\u00f8hmer","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0535","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s12098-010-0332-6","article-title":"Cerebellar atrophy in a child with valproate toxicity","volume":"78","author":"Ghosh","year":"2011","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0540","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.pnpbp.2010.02.017","article-title":"Valproate-induced hyperammonemia in mental retardation: a case report and review of the literature","volume":"34","author":"Khoo","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0545","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/JCP.0b013e31822cd2a0","article-title":"Carnitine supplementation for valproate-related hyperammonemia to maintain therapeutic valproate level","volume":"31","author":"Sonik","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0550","doi-asserted-by":"crossref","first-page":"84.e3","DOI":"10.1016\/j.genhosppsych.2010.10.004","article-title":"The real mechanism of VPA-induced hyperammonemia remains unknown","volume":"33","author":"Hung","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0555","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1176\/jnp.23.1.jnpe22","article-title":"Valproate-induced encephalopathy related to concurrent antimanic medications","volume":"23","author":"Trojak","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0560","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1442-200X.2010.03157.x","article-title":"Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia","volume":"52","author":"Yagi","year":"2010","journal-title":"Pediatr Int"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0565","series-title":"Drug-induced hepatotoxicity","first-page":"611","article-title":"Alcohol-induced liver injury","author":"Israel","year":"1996"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0570","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00004714-200212000-00019","article-title":"Valproate-induced hyperammonaemia","volume":"22","author":"Raja","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0575","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2146\/ajhp110049","article-title":"Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy","volume":"69","author":"Mock","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0580","first-page":"627","article-title":"Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)\u2014a study from tertiary care referral university hospital, north India","volume":"58","author":"Mehndiratta","year":"2008","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0585","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/JCP.0b013e318240a4a7","article-title":"Ammonemia in bipolar patients on maintenance treatment with valproic acid","volume":"32","author":"Bocchetta","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0590","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11633090-000000000-00000","article-title":"Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study","volume":"26","author":"Hottinger","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0595","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2009.04.002","article-title":"The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status","volume":"86","author":"Hamed","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0600","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1345\/aph.1P135","article-title":"l-carnitine for acute valproic acid overdose: a systematic review of published cases","volume":"44","author":"Perrott","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0605","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/02699050903302344","article-title":"Valproic acid-induced encephalopathy in very long course treated patients","volume":"23","author":"Rousseau","year":"2009","journal-title":"Brain Inj"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0610","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eplepsyres.2009.02.012","article-title":"Hyperammonemia following intravenous valproate loading","volume":"85","author":"DeWolfe","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0615","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(63)90554-3","article-title":"Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood","volume":"2","author":"Reye","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0620","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0387-7604(83)80029-1","article-title":"Reye-like syndrome associated with valproic acid","volume":"5","author":"Sugimoto","year":"1983","journal-title":"Brain Dev"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0625","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0022-3565(25)20745-5","article-title":"The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury","volume":"278","author":"Trost","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0630","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0022-3476(79)80110-9","article-title":"Reye-like syndrome associated with valproic acid therapy","volume":"95","author":"Gerber","year":"1979","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0635","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.410070423","article-title":"Fatal Reye-like syndrome associated with valproic acid","volume":"7","author":"Young","year":"1980","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0640","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF01377353","article-title":"Decreased serum carnitine in valproate induced Reye syndrome","volume":"139","author":"B\u00f6hles","year":"1982","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0645","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0140-6736(85)91481-3","article-title":"Valproic acid associated abnormalities of carnitine metabolism","volume":"1","author":"Murphy","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0650","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1353\/pbm.1968.0004","article-title":"The spectrum of hepatotoxicity","volume":"12","author":"Zimmerman","year":"1968","journal-title":"Perspect Biol Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0655","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1172\/JCI113798","article-title":"Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk","volume":"82","author":"Shear","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0660","series-title":"Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver","author":"Zimmerman","year":"1999"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0665","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0009-9120(00)00146-6","article-title":"A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes","volume":"33","author":"Neuman","year":"2000","journal-title":"Clin Biochem"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0670","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/00007691-200212000-00008","article-title":"Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals","volume":"24","author":"Neuman","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0675","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/157488606777934459","article-title":"Antiepileptic drug-induced hypersensitivity syndrome reactions","volume":"1","author":"Krivoy","year":"2006","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0680","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.trsl.2006.12.005","article-title":"Apoptosis in ibuprofen-induced Stevens\u2013Johnson syndrome","volume":"149","author":"Neuman","year":"2007","journal-title":"Transl Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0685","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.trsl.2006.12.001","article-title":"Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides","volume":"149","author":"Neuman","year":"2007","journal-title":"Transl Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0690","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1600-0625.2008.00748.x","article-title":"Predicting possible zonisamide hypersensitivity syndrome","volume":"17","author":"Neuman","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0695","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.trsl.2010.01.005","article-title":"Ibuprofen-induced hypersensitivity syndrome","volume":"155","author":"Nanau","year":"2010","journal-title":"Transl Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0700","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.trsl.2012.01.004","article-title":"Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs","volume":"159","author":"Neuman","year":"2012","journal-title":"Transl Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0705","doi-asserted-by":"crossref","first-page":"723062","DOI":"10.1155\/2012\/723062","article-title":"The Link between Hypersensitivity Syndrome Reaction Development and Human Herpes Virus-6 Reactivation","volume":"2012","author":"Pritchett","year":"2012","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0710","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous membrane involvement and Stevens\u2013Johnson syndrome are clinically different disorders with distinct causes","volume":"131","author":"Assier","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0715","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0720","first-page":"865","article-title":"Multiple drug allergy in patients with cutaneous adverse drug reactions diagnosed by in vitro drug-induced interferon-gamma release","volume":"10","author":"Halevy","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0725","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0730","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1212\/WNL.0b013e31823b478c","article-title":"Severe cutaneous adverse reactions to antiepileptic drugs in Asians","volume":"77","author":"Yang","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0735","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1212\/WNL.49.2.542","article-title":"Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study","volume":"49","author":"Tennis","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0740","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1592\/phco.27.10.1425","article-title":"Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care","volume":"27","author":"Bohan","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0745","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/j.1365-4632.2008.03827.x","article-title":"Anticonvulsant hypersensitivity syndrome: clinical and laboratory features","volume":"47","author":"Mansur","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0750","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1590\/S0004-282X1996000100008","article-title":"Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk","volume":"54","author":"Li","year":"1996","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0755","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00002018-200022040-00003","article-title":"The tolerability of lamotrigine in children","volume":"22","author":"Messenheimer","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0760","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/j.1875-9114.1998.tb03868.x","article-title":"Fatal toxic epidermal necrolysis related to lamotrigine administration","volume":"18","author":"Page","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0765","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1525-1470.1999.99014.x","article-title":"Hypersensitivity reaction in a child due to lamotrigine","volume":"16","author":"Brown","year":"1999","journal-title":"Pediatr Dermatol"},{"issue":"Suppl. 5","key":"10.1016\/j.clinbiochem.2013.06.012_bb0770","first-page":"S30","article-title":"Lamotrigine","volume":"40","author":"Matsuo","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0775","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.seizure.2010.09.003","article-title":"Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population","volume":"19","author":"Wang","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0780","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000070760","article-title":"Anticonvulsant hypersensitivity syndrome: report of 2 cases from Kuwait","volume":"12","author":"Bin-Nakhi","year":"2003","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0785","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1176\/appi.ajp.162.5.1021","article-title":"Anticonvulsant hypersensitivity syndrome from addition of lamotrigine to divalproex","volume":"162","author":"Rahman","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0790","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.pnpbp.2005.11.033","article-title":"Lamotrigine-associated anticonvulsant hypersensitivity syndrome in bipolar disorder","volume":"30","author":"Chang","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0795","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/MEJ.0b013e3283311f04","article-title":"Multiple organ dysfunction syndrome: infection or hypersensitivity reaction?","volume":"17","author":"Dreesman","year":"2010","journal-title":"Eur J Emerg Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0800","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0805","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-0536.1999.tb06105.x","article-title":"Hypersensitivity syndrome due to 2 anticonvulsant drugs","volume":"41","author":"Conilleau","year":"1999","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0810","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2340\/00015555-0049","article-title":"Drug rash with eosinophilia and systemic symptoms induced by valproate and carbamazepine: formation of circulating auto-antibody against 190-kDa antigen","volume":"86","author":"Yun","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0815","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1525-1470.2007.00566.x","article-title":"A recurrent drug rash with eosinophilia and systemic symptoms","volume":"24","author":"Ben Salem","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0820","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00296-010-1463-9","article-title":"DRESS syndrome with fatal results induced by sodium valproate in a patient with brucellosis and a positive cytoplasmic antineutrophilic cytoplasmic antibody test result","volume":"32","author":"Albayrak","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0825","first-page":"155","article-title":"Valproic acid-induced DRESS syndrome with acute liver failure","volume":"70","author":"van Zoelen","year":"2012","journal-title":"Neth J Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0830","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/0883073809343474","article-title":"Valproic acid-associated vanishing bile duct syndrome","volume":"25","author":"G\u00f6k\u00e7e","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0835","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1542\/peds.2008-1923","article-title":"Medications as risk factors of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis","volume":"123","author":"Levi","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0840","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case\u2013control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0845","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","article-title":"Risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics","volume":"64","author":"Mockenhaupt","year":"2005","journal-title":"Neurology"},{"issue":"Suppl. 7","key":"10.1016\/j.clinbiochem.2013.06.012_bb0850","first-page":"S22","article-title":"Lamotrigine-induced severe cutaneous adverse reactions","volume":"39","author":"Schlienger","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0855","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pnpbp.2005.08.025","article-title":"Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder","volume":"30","author":"Chang","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0860","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/00002018-199921060-00005","article-title":"Anticonvulsant hypersensitivity syndrome: incidence, prevention and management","volume":"21","author":"Knowles","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0865","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1346-8138.2009.00770.x","article-title":"Toxic epidermal necrolysis with severe hyperbilirubinemia: complete re-epithelialization after bilirubin reduction therapies","volume":"37","author":"Kamada","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0870","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ajp.161.3.579","article-title":"Valproic acid and hypersensitivity syndrome","volume":"161","author":"Roepke","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0875","first-page":"100","article-title":"Intravenous valproate for seizures in 137 Taiwanese children\u2014valproate naive and non-naive","volume":"19","author":"Chang","year":"2010","journal-title":"Acta Neurol Taiwan"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0880","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4103\/0028-3886.51302","article-title":"Unusual cutaneous reaction with sodium valproate","volume":"57","author":"Roy","year":"2009","journal-title":"Neurol India"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0885","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0190-9622(97)70292-5","article-title":"Fixed drug eruption to three anticonvulsant drugs: an unusual case of polysensitivity","volume":"36","author":"Chan","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0890","first-page":"444","article-title":"Toxic epidermal necrolysis associated to the use of valproic acid","volume":"50","author":"Guevara-Campos","year":"2010","journal-title":"Rev Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0895","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2125.2003.01816.x","article-title":"Antiepileptic drug hypersensitivity syndrome in a patient treated with valproate","volume":"55","author":"Ar\u00e9valo-Lorido","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0900","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00128071-200708020-00007","article-title":"Stevens\u2013Johnson syndrome due to concomitant use of lamotrigine and valproic acid","volume":"8","author":"Kocak","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0905","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-4632.2009.03865.x","article-title":"A case with Stevens Johnson syndrome triggered by combination of clobazam, lamotrigine, and valproic acid treatment","volume":"48","author":"Ertam","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0910","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0140-6736(91)93438-F","article-title":"Cutaneous vasculitis induced by sodium valproate","volume":"337","author":"Kamper","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0915","first-page":"215","article-title":"Valproate-acid-induced cutaneous leukocytoclastic vasculitis","volume":"24","author":"Lasi\u0107","year":"2012","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0920","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1046\/j.1365-2133.2001.04240.x","article-title":"Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine","volume":"144","author":"Cogrel","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0925","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/epi.12028","article-title":"Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12months","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0930","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.seizure.2010.06.014","article-title":"Quality of life and treatment satisfaction in Spanish epilepsy patients on monotherapy with lamotrigine or valproic acid","volume":"19","author":"Viteri","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0935","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2010.09.014","article-title":"A 6-month prospective study on efficacy safety and QOL profiles of extended-release formulation of valproate in patients with epilepsy","volume":"20","author":"Yu","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0940","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1440-1819.2008.01877.x","article-title":"Postural induced-tremor in psychiatry","volume":"62","author":"Arbaizar","year":"2008","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0945","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1182\/blood-2011-04-349910","article-title":"Safety of long-term treatment of HAM\/TSP patients with valproic acid","volume":"118","author":"Olindo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0950","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0028-1102912","article-title":"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database","volume":"42","author":"Bondon-Guitton","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0955","first-page":"CD009183","article-title":"Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults","volume":"10","author":"Gill","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0960","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1399-5618.2011.00898.x","article-title":"Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study","volume":"13","author":"Marcus","year":"2011","journal-title":"Bipolar Disord"},{"issue":"Suppl. 1","key":"10.1016\/j.clinbiochem.2013.06.012_bb0965","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.archger.2009.09.019","article-title":"Valproate-induced delirium in a demented patient","volume":"49","author":"Gareri","year":"2009","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0970","doi-asserted-by":"crossref","first-page":"446.e1","DOI":"10.1016\/j.genhosppsych.2009.06.005","article-title":"Unexpected interaction between quetiapine and valproate in patients with bipolar disorder","volume":"32","author":"Huang","year":"2010","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0975","first-page":"79","article-title":"Valproate induced hypoactive delirium in a bipolar disorder patient with psychotic features","volume":"21","author":"\u00d6zen","year":"2010","journal-title":"Turk Psikiyatri Derg"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0980","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.lpm.2009.02.024","article-title":"Iatrogenic dementia and extrapyramidal syndrome: rare adverse effect of valproic acid-aspirin combination","volume":"39","author":"Penot","year":"2010","journal-title":"Presse Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0985","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1532-5415.2010.02795.x","article-title":"Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus","volume":"58","author":"Sleegers","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0990","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.seizure.2011.02.009","article-title":"Reversible dementia and gait disturbance after prolonged use of valproic acid","volume":"20","author":"Evans","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb0995","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/mds.23119","article-title":"Valproate-induced reversible hemichorea","volume":"25","author":"Srinivasan","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1000","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","article-title":"Drug-induced parkinsonism: a review of 17years' experience in a regional pharmacovigilance center in France","volume":"26","author":"Bondon-Guitton","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.amjopharm.2011.09.002","article-title":"Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature","volume":"9","author":"Mahmoud","year":"2011","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1010","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2710.2010.01197.x","article-title":"Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine","volume":"36","author":"De Dios","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1015","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00467-011-1796-y","article-title":"Regulation of kidney development by histone deacetylases","volume":"26","author":"Rosenberg","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pediatrneurol.2009.12.003","article-title":"Fanconi syndrome caused by valproic acid","volume":"42","author":"Endo","year":"2010","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1025","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s11606-011-1708-7","article-title":"Valproate-induced Fanconi syndrome in a 27-year-old woman","volume":"26","author":"Patel","year":"2011","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0387-7604(02)00007-4","article-title":"Tubulo-interstitial nephritis caused by sodium valproate","volume":"24","author":"Yoshikawa","year":"2002","journal-title":"Brain Dev"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-0031-1279783","article-title":"Fractures and Fanconi syndrome due to prolonged sodium valproate use","volume":"42","author":"Dhillon","year":"2011","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1040","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/adc.2008.148932","article-title":"Valproate and risk of fracture in Rett syndrome","volume":"95","author":"Leonard","year":"2010","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1045","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1176\/appi.neuropsych.11010023","article-title":"Levocarnitine-induced hypophosphatemia in a hemodialysis patient with acute valproic acid toxicity","volume":"24","author":"Prohaska","year":"2012","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/0028-3886.63796","article-title":"Early predisposition to osteomalacia in Indian adults on phenytoin or valproate monotherapy and effective prophylaxis by simultaneous supplementation with calcium and 25-hydroxy vitamin D at recommended daily allowance dosage: a prospective study","volume":"58","author":"Krishnamoorthy","year":"2010","journal-title":"Neurol India"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12098-009-0005-5","article-title":"Bone metabolism alteration on antiepileptic drug therapy","volume":"76","author":"Krishnamoorthy","year":"2009","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2009.12.015","article-title":"Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy","volume":"290","author":"Triantafyllou","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1065","first-page":"50","article-title":"Hemostatic disorders caused by chronic use of valproic acid in neurosurgical patients. Thromboelastographic monitoring","volume":"4","author":"Israelian","year":"2010","journal-title":"Anesteziol Reanimatol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-0037-1617026","article-title":"Acquired von Willebrand syndrome as side effect of valproic acidtherapy in children is rare","volume":"29","author":"Eberl","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1075","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1177\/0883073808331084","article-title":"Valproate-associated coagulopathies in children during short-term treatment","volume":"24","author":"K\u00f6se","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2008.10.005","article-title":"Thrombophilic risk factors in epileptic children treated with valproic acid","volume":"40","author":"\u00dcnal","year":"2009","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1752-1947-6-239","article-title":"Anemia secondary to valproic acid therapy in a 13-year-old boy: a case report","volume":"6","author":"Kaczorowska-Hac","year":"2012","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1090","first-page":"345","article-title":"A rare occurrence of isolated neutropenia with valproic acid: a case report","volume":"109","author":"Chakraborty","year":"2011","journal-title":"J Indian Med Assoc"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1095","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/JCP.0b013e3182549d2d","article-title":"Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients","volume":"32","author":"Hung","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/JCP.0b013e31823f87e5","article-title":"Quetiapine- and valproate-associated neutropenia and thrombocytopenia after lamotrigine-induced Steven\u2013Johnson syndrome","volume":"32","author":"Chang","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1105","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1345\/aph.1L617","article-title":"Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents","volume":"43","author":"Rahman","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1110","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/JCP.0b013e3181db2684","article-title":"Hematological effects of valproate in psychiatric patients: what are the risk factors?","volume":"30","author":"Vasudev","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","article-title":"Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis","volume":"53","author":"Chuang","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1120","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.braindev.2008.11.001","article-title":"Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid","volume":"31","author":"Erdemir","year":"2009","journal-title":"Brain Dev"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1125","first-page":"e5","article-title":"Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents","volume":"17","author":"Cheng","year":"2010","journal-title":"Can J Clin Pharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.amjopharm.2010.04.005","article-title":"Probablevalproate sodium-associated hypotension","volume":"8","author":"Ota","year":"2010","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1135","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11940-010-0080-y","article-title":"Antiepileptic drugs and markers of vascular risk","volume":"12","author":"Lopinto-Khoury","year":"2010","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.seizure.2010.12.011","article-title":"Gastrointestinal adverse effects of antiepileptic drugs in intractable epileptic patients","volume":"20","author":"Jahromi","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1145","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.braindev.2011.08.007","article-title":"Long-term effectiveness of ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy","volume":"34","author":"Hwang","year":"2012","journal-title":"Brain Dev"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1150","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(79)91885-3","article-title":"Pancreatitis due to valproic acid","volume":"1","author":"Campfield","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1155","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/0016-5085(81)90148-7","article-title":"Recurrent pancreatitis induced by valproic acid","volume":"80","author":"Parker","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1160","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/adc.58.7.543","article-title":"Pancreatitis during sodium valproate treatment","volume":"58","author":"Williams","year":"1983","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1165","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s10620-010-1277-3","article-title":"Incidence, severity, and etiology of drug-induced acute pancreatitis","volume":"55","author":"Vinklerov\u00e1","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1170","first-page":"581","article-title":"Drug-induced acute pancreatitis in a cohort of 328 patients. A single-centre experience from Australia","volume":"12","author":"Barreto","year":"2011","journal-title":"JOP"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1175","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1590\/S0004-282X2009000300028","article-title":"Acute pancreatitis associated to the use of valproic acid","volume":"67","author":"Guevara-Campos","year":"2009","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1590\/S0004-282X2010000100029","article-title":"Valproic acid-induced pancreatitis in an adult","volume":"68","author":"Santos","year":"2010","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1185","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ejpn.2011.04.004","article-title":"VPA-induced recurrent pancreatitis in a cystic fibrosis carrier","volume":"15","author":"Dinopoulos","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1190","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/j.1468-1331.2011.03409.x","article-title":"Valproate associated diffuse alveolar hemorrhage","volume":"18","author":"Choi","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1195","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ppul.20982","article-title":"Fungal pleural effusion secondary to a rare cause of pancreatic pseudocyst","volume":"44","author":"Gupta","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1345\/aph.1L414","article-title":"Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy","volume":"43","author":"Grosso","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1205","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jad.2009.12.011","article-title":"The role of valproate in metabolic disturbances in bipolar disorder patients","volume":"124","author":"Chang","year":"2010","journal-title":"J Affect Disord"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1210","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1590\/S0004-282X2010000200024","article-title":"Modification in body weight associated with antiepileptic drugs","volume":"68","author":"Gaspari","year":"2010","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1215","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/0883073808323023","article-title":"Weight gain in children treated with valproate","volume":"24","author":"Sharpe","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1220","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/0883073809349461","article-title":"Weight gain and insulin resistance in children treated with valproate: the influence of time","volume":"25","author":"Masuccio","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1225","first-page":"125","article-title":"Valproate-induced insulin resistance and obesity in children","volume":"71","author":"Verrotti","year":"2009","journal-title":"Horm Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1230","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/00048670802534341","article-title":"Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls","volume":"43","author":"Elmslie","year":"2009","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1235","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1528-1167.2009.02206.x","article-title":"The metabolic syndrome in overweight epileptic patients treated withvalproic acid","volume":"51","author":"Verrotti","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1240","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/JCP.0b013e31820f4f9e","article-title":"Rapid development of severe hypertriglyceridemia and hypercholesterolemia during augmentation of quetiapine with valproic acid","volume":"31","author":"Liang","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1245","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/JCP.0b013e3181f03f50","article-title":"C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients","volume":"30","author":"Chang","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1250","first-page":"128","article-title":"Selected neurologic disorders related to polycystic ovary syndrome","volume":"83","author":"Krepu\u0142a","year":"2012","journal-title":"Ginekol Pol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1255","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.reprotox.2011.02.002","article-title":"Hormonal and reproductive disturbances in epileptic male patients: emerging issues","volume":"31","author":"Verrotti","year":"2011","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1260","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jadohealth.2008.11.010","article-title":"Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents","volume":"45","author":"Jerrell","year":"2009","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1265","first-page":"795","article-title":"Endocrine effects of antiepileptic drugs","volume":"65","author":"Le\u015bkiewicz","year":"2008","journal-title":"Przegl Lek"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1270","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1528-1167.2010.02897.x","article-title":"Antiepileptic drugs, sex hormones, and PCOS","volume":"52","author":"Verrotti","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1275","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.eplepsyres.2009.11.003","article-title":"Effects of levetiracetam and valproic acid monotherapy on sex-steroid hormones in prepubertal children\u2014results from a pilot study","volume":"88","author":"Rauchenzauner","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1280","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/09513590802288259","article-title":"Polycystic ovary syndrome in women using valproate: a review","volume":"24","author":"Bilo","year":"2008","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1285","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eplepsyres.2011.07.006","article-title":"A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy","volume":"97","author":"Hu","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1290","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000203537","article-title":"Long-term effects of valproic acid on reproductive endocrine functions in Turkish women with epilepsy","volume":"67","author":"Gorkemli","year":"2009","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1295","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/11318950-000000000-00000","article-title":"Syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatraemia associated with valproic acid: four case reports from the Netherlands and a case\/non-case analysis of vigibase","volume":"33","author":"Beers","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1300","first-page":"6","article-title":"Inappropriate antidiuretic hormone secretion induced by sodium valproate","volume":"65","author":"B\u00e8ve","year":"2010","journal-title":"Rev Med Liege"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1305","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/0883073811421985","article-title":"Evaluation of subclinical hypothyroidism in ambulatory children with controlled epilepsy on valproate monotherapy","volume":"27","author":"Sahu","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1310","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1530\/EJE-08-0325","article-title":"Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate","volume":"160","author":"Verrotti","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1315","first-page":"200.e13-5","article-title":"Decreased thyroid function in Korean women with bipolar disorder receiving valproic acid","volume":"33","author":"Park","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1320","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/WNF.0b013e31823429a7","article-title":"Thyroid adverse effects of psychotropic drugs: a review","volume":"34","author":"Bou Khalil","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1325","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0013-9580.2004.26003.x","article-title":"Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication","volume":"45","author":"Vainionp\u00e4\u00e4","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1330","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1017\/S1047951110000697","article-title":"Assessment of low-density lipoprotein oxidation, paraoxonase activity, and arterial distensibility in epileptic children who were treated with anti-epileptic drugs","volume":"20","author":"Yildiz","year":"2010","journal-title":"Cardiol Young"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1335","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pediatrneurol.2011.04.005","article-title":"Thyroid hormone levels in children receiving carbamazepine or valproate","volume":"45","author":"Aggarwal","year":"2011","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1340","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/00207454.2011.627486","article-title":"Thyroid hormones in children on antiepileptic therapy","volume":"122","author":"Ayg\u00fcn","year":"2012","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1345","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yebeh.2009.07.014","article-title":"Reversible effects of antiepileptic drugs on thyroid hormones in men and women with epilepsy: a prospective randomized double-blind withdrawal study","volume":"16","author":"Lossius","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1350","first-page":"37434","volume":"44","author":"U.S. Food and Drug Administration","year":"1980"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1355","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1360","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1176\/ps.62.2.pss6202_0218","article-title":"Valproate prescription prevalence among women of childbearing age","volume":"62","author":"Wisner","year":"2011","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1365","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/11589170-000000000-00000","article-title":"Drug prescribing before and during pregnancy in south west France: a retrolective study","volume":"34","author":"Crespin","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1370","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/adc.2008.144386","article-title":"Changing trends in antiepileptic drug prescribing in girls of child-bearing potential","volume":"94","author":"Ackers","year":"2009","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1375","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0404.2009.01260.x","article-title":"Changing patterns of antiepileptic drug use in pregnant Australian women","volume":"121","author":"Vajda","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1380","first-page":"253","article-title":"Valproic acid: long-term effects on children exposed in utero","volume":"18","author":"Anonymous","year":"2009","journal-title":"Prescrire Int"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-200629010-00001","article-title":"Valproic acid in epilepsy: pregnancy-related issues","volume":"29","author":"Genton","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1390","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2174\/138920111795470958","article-title":"Antiepileptic drugs during pregnancy: pharmacokinetics and transplacental transfer","volume":"12","author":"De Santis","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1395","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2005.06.001","article-title":"Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development","volume":"65","author":"Eriksson","year":"2005","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1400","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.yebeh.2009.09.024","article-title":"A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy","volume":"16","author":"McVearry","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1405","first-page":"165","article-title":"Rare but real-the effects of sodium valproate in pregnancy","volume":"104","author":"Reardon","year":"2011","journal-title":"Ir Med J"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1410","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/11317640-000000000-00000","article-title":"Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies","volume":"33","author":"Banach","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1415","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/j.1528-1167.2010.02668.x","article-title":"Early cognitive development in children born to women with epilepsy: a prospective report","volume":"51","author":"Bromley","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1420","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1425","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1474-4422(09)70154-1","article-title":"Cognitive outcome after exposure to antiepileptic drugs in utero","volume":"8","author":"Battino","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1430","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMc091029","article-title":"Cognitive function after fetal exposure to antiepileptic drugs","volume":"361","author":"Liu","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1435","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1017\/S1355617710001359","article-title":"The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy","volume":"17","author":"Nadebaum","year":"2011","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1440","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1212\/WNL.0b013e318202f559","article-title":"Seizure medications, pregnancy, and breastfeeding","volume":"75","author":"Karceski","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1445","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.neubiorev.2010.12.013","article-title":"Fetal exposure to teratogens: evidence of genes involved in autism","volume":"35","author":"Dufour-Rainfray","year":"2011","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1450","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1111\/j.1528-1167.2009.02147.x","article-title":"Pregnancy, delivery, and outcome for the child in maternal epilepsy","volume":"50","author":"Veiby","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1455","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1528-1157.1997.tb01480.x","article-title":"Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy","volume":"38","author":"Samr\u00e9n","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1460","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1651-2227.2004.tb00701.x","article-title":"Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study","volume":"93","author":"Wide","year":"2004","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1465","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMoa0907328","article-title":"Valproic acid monotherapy in pregnancy and major congenital malformations","volume":"362","author":"Jentink","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1470","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ajmg.c.30306","article-title":"Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States","volume":"157","author":"Gilboa","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1475","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.annepidem.2011.08.002","article-title":"Use of antiepileptic medications in pregnancy in relation to risks of birth defects","volume":"21","author":"Werler","year":"2011","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1480","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.reprotox.2010.03.005","article-title":"Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the international Clearinghouse of birth defects surveillance and research","volume":"29","author":"Lisi","year":"2010","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1485","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1002\/ajmg.a.33633","article-title":"Tibial developmental field defect in valproic acid embryopathy: report on three cases","volume":"152A","author":"Alessandri","year":"2010","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1490","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MCD.0b013e3283155170","article-title":"Fibular aplasia in a child exposed to sodium valproate in pregnancy","volume":"18","author":"Cole","year":"2009","journal-title":"Clin Dysmorphol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1495","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/14767058.2010.501120","article-title":"Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly","volume":"24","author":"Ozkan","year":"2011","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1500","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMc1008255","article-title":"Valproic acid use in pregnancy and congenital malformations","volume":"363","author":"Vajda","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1505","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1468-1331.2006.01359.x","article-title":"Foetal malformations and seizure control: 52months data of the Australian Pregnancy Registry","volume":"13","author":"Vajda","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1510","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.seizure.2012.01.005","article-title":"Valproate and the risk for congenital malformations: is formulation and dosage regime important?","volume":"21","author":"Mawhinney","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1515","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1520","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.2005.074203","article-title":"Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register","volume":"77","author":"Morrow","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1525","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/ajmg.a.35438","article-title":"Antiepileptic drugs and pregnancy outcomes","volume":"158A","author":"Wlodarczyk","year":"2012","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1530","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1528-1167.2009.02336.x","article-title":"The teratogenic risk of antiepileptic drug polytherapy","volume":"51","author":"Vajda","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1535","first-page":"221","article-title":"Valproate treatment during pregnancy: description of four cases with foetal valproate syndrome","volume":"171","author":"Sabers","year":"2009","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1540","first-page":"288","article-title":"A case of fetal valproate syndrome with new features expanding the phenotype","volume":"30","author":"Seidahmed","year":"2009","journal-title":"Saudi Med J"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1545","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/0256-4947.62839","article-title":"Fetal valproate syndrome in a 2-month-old male infant","volume":"30","author":"Zaki","year":"2010","journal-title":"Ann Saudi Med"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1550","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1212\/WNL.0b013e3181ffe4a9","article-title":"Effects of breastfeeding in children of women taking antiepileptic drugs","volume":"75","author":"Meador","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.clinbiochem.2013.06.012_bb1555","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1212\/WNL.0b013e3181ff94d5","article-title":"Antiepileptic drugs and breastfeeding: do we tell women \u201cno\u201d?","volume":"75","author":"Klein","year":"2010","journal-title":"Neurology"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912013002890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912013002890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:43:26Z","timestamp":1757864606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912013002890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":311,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0009912013002890"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2013.06.012","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse drug reactions induced by valproic acid","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2013.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}